Why a common drug for certain forms of acute lymphoblastic leukemia’t have found out by researchers at the University of Frankfurt together with international colleagues. Acute lymphocytic leukemia is the most common cancer in children.
Sascha Zoske
sheet-makers in the Rhein-Main-Zeitung.
F. A. Z.
his cells are Similar to the T-lymphocytes of the immune system, is the disease with the active ingredient Nelarabine is well treatable. The cancer cells are related to in contrast with B lymphocytes, not at the same time, this therapy often.
As the study of scientists led by Jindrich Cinatl shows, it is due to an enzyme called SAMDH1. It ensures that the Nelarabine is inactivated in the cells. Leukemia cells of B-type contain more SAMDH1 than the T variants.
The enzyme can therefore be used as a Marker that shows how well a Patient on Nelarabine responsive. Because sometimes B-leukemia cells form little SAMDH1, could come the drug in such cases, exceptionally, to use.